Group 1 - Aktis Oncology is a clinical-stage biotechnology company focused on developing targeted radiopharmaceuticals for the treatment of solid tumors, planning to list on NASDAQ by issuing 17.7 million shares at $18 each, raising $318 million [1] - The company initially planned to issue 11.8 million shares but expanded the offering size, with Eli Lilly (LLY.US) committing to purchase $100 million worth of shares [1] - Following the pricing, Aktis's fully diluted market capitalization reached $1 billion [1] Group 2 - Aktis Oncology's pipeline includes Ac-AKY-1189, targeting Nectin-4 expressing cancers, currently in a multi-center Phase 1b clinical trial with approximately 150 patients recruited, expecting preliminary results in Q1 2027 [1] - The company is also developing Ac-AKY-2519 for B7-H3 expressing tumors, with plans to submit an Investigational New Drug (IND) application in 2026 [1] - Aktis manages several domestic and international isotope supply partnerships and is investing in an internal cGMP facility expected to be operational by 2026, while collaborating with partners on additional mini-protein radioconjugate projects [1]
今晚登陆纳斯达克！Aktis Oncology(AKTS.US)IPO定价每股18美元